Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VisEn Medical Inc.

This article was originally published in Start Up

Executive Summary

VisEn Medical's core technology is based on activatable "smart imaging agents" and novel optical systems, including fluorescence-mediated tomography. The ability to visualize reactions and processes in vivo in real time using agents specifically activated by molecular targets, processes, or pathways-the molecular signatures of disease--may lead to breakthroughs that aren't possible with in vitro methods.

You may also be interested in...

Sloan-Kettering Shines a Light on Nanotech Imaging

Researchers at Memorial Sloan-Kettering and Cornell University have taken the first steps toward moving a silica-based nanoparticle platform invented at Cornell into use in cancer imaging. Using optical imaging and PET, they showed that encapsulating a dye in a biocompatible nanoscale matrix enhanced imaging capabilities while maintaining efficient clearance through the urine.

Imaging in its Heyday: Research Applications (Part 1)

Biomolecular imaging is upgrading diagnostic imaging's stodgy reputation as scientists increasingly use it to improve both pharmaceutical research and clinical care. Part I of a two-part series explores researchers' excitement about biomolecular imaging's potential to improve the drug development process. Many companies see research applications as a way to prime the marketplace for clinical applications. But venture capitalists think research is a limited opportunity.

Science Matters: Harnessing The Inherent Power Of MAIT Cells

Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts